Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia

Article Public, Environmental & Occupational Health

Vital Signs: Health Disparities in Hemodialysis-Associated Staphylococcus aureus Bloodstream Infections — United States, 2017–2020

Brian Rha et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2023)

Article Immunology

Black and White Patients With Staphylococcus aureus Bacteremia Have Similar Outcomes but Different Risk Factors

Felicia Ruffin et al.

Summary: The study found that Black and White patients with Staphylococcus aureus bacteremia had similar outcomes, despite differences in age, diabetes, and hemodialysis dependence. The results highlight the need for further research on the reasons behind the disparities.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Review Infectious Diseases

Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis

Anthony D. Bai et al.

Summary: The mortality rate of Staphylococcus aureus bacteremia has decreased over the past three decades, but one in four patients still die within three months. Methicillin-resistant Staphylococcus aureus infection is associated with a higher mortality rate, while more recent time periods have shown lower mortality rates.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Article Immunology

Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)

J. Scott Overcash et al.

Summary: The study demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, showing comparable early clinical response rates and investigator-assessed clinical success at the TOC visit.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Microbiology